Stryker Co. (NYSE:SYK) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Stryker Co. (NYSE:SYK) have been given a consensus rating of “Moderate Buy” by the twenty ratings firms that are covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $420.68.

Several research analysts have commented on the company. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $370.00 to $445.00 in a research report on Monday, December 2nd. Canaccord Genuity Group lifted their price target on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Royal Bank of Canada lifted their price target on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, Evercore ISI lifted their price target on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th.

Stryker Price Performance

SYK stock opened at $385.05 on Monday. The business has a 50 day moving average price of $377.31 and a 200 day moving average price of $366.92. The stock has a market cap of $146.79 billion, a price-to-earnings ratio of 49.62, a PEG ratio of 2.98 and a beta of 0.96. Stryker has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the business earned $3.46 earnings per share. Equities research analysts anticipate that Stryker will post 13.49 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is presently 43.30%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 5.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Kohmann Bosshard Financial Services LLC purchased a new stake in Stryker during the fourth quarter worth $25,000. Dunhill Financial LLC boosted its position in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares in the last quarter. Rakuten Securities Inc. boosted its position in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after purchasing an additional 68 shares in the last quarter. Centricity Wealth Management LLC purchased a new stake in Stryker during the fourth quarter worth $30,000. Finally, BankPlus Trust Department purchased a new stake in Stryker during the fourth quarter worth $33,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.